295 related articles for article (PubMed ID: 15990761)
21. Outcomes of acute coronary syndrome in a large Canadian cohort: impact of chronic renal insufficiency, cardiac interventions, and anemia.
Keough-Ryan TM; Kiberd BA; Dipchand CS; Cox JL; Rose CL; Thompson KJ; Clase CM
Am J Kidney Dis; 2005 Nov; 46(5):845-55. PubMed ID: 16253724
[TBL] [Abstract][Full Text] [Related]
22. [Effect of combined beta-blocker and angiotensin-converting enzyme inhibitor treatment on 1-year survival after acute myocardial infarction: findings of the PRIAMHO-II registry].
Arós F; Loma-Osorio A; Vila J; López-Bescós L; Cuñat J; Rodríguez E; San José JM; Heras M; Marrugat J;
Rev Esp Cardiol; 2006 Apr; 59(4):313-20. PubMed ID: 16709383
[TBL] [Abstract][Full Text] [Related]
23. [Renal failure is an independent predictor of mortality in hospitalized heart failure patients and is associated with a worse cardiovascular risk profile].
Grigorian Shamagian L; Varela Román A; Pedreira Pérez M; Gómez Otero I; Virgós Lamela A; González-Juanatey JR
Rev Esp Cardiol; 2006 Feb; 59(2):99-108. PubMed ID: 16540030
[TBL] [Abstract][Full Text] [Related]
24. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors.
Morimoto T; Gandhi TK; Fiskio JM; Seger AC; So JW; Cook EF; Fukui T; Bates DW
J Eval Clin Pract; 2004 Nov; 10(4):499-509. PubMed ID: 15482412
[TBL] [Abstract][Full Text] [Related]
25. Association of blood pressure and its evolving changes with the survival of patients with heart failure.
Grigorian-Shamagian L; Gonzalez-JuAnatey JR; Vazquez R; Cinca J; Bayes-Genis A; Pascual D; Fernandez-Palomeque C; Bardaji A; Almendral J; Nieto V; Macaya C; Jimenez RP; de Luna AB;
J Card Fail; 2008 Sep; 14(7):561-8. PubMed ID: 18722321
[TBL] [Abstract][Full Text] [Related]
26. Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure.
Chen YT; Wang Y; Radford MJ; Krumholz HM
Am Heart J; 2001 Mar; 141(3):410-7. PubMed ID: 11231438
[TBL] [Abstract][Full Text] [Related]
27. Does aspirin use adversely influence intermediate-term postdischarge outcomes for hospitalized patients who are treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? Findings from Organized Program to Facilitate Life-Saving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
Levy PD; Nandyal D; Welch RD; Sun JL; Pieper K; Ghali JK; Fonarow GC; Gheorghiade M; O'Connor CM
Am Heart J; 2010 Feb; 159(2):222-230.e2. PubMed ID: 20152220
[TBL] [Abstract][Full Text] [Related]
28. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study.
Klein L; O'Connor CM; Leimberger JD; Gattis-Stough W; Piña IL; Felker GM; Adams KF; Califf RM; Gheorghiade M;
Circulation; 2005 May; 111(19):2454-60. PubMed ID: 15867182
[TBL] [Abstract][Full Text] [Related]
29. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
O'Connor CM; Abraham WT; Albert NM; Clare R; Gattis Stough W; Gheorghiade M; Greenberg BH; Yancy CW; Young JB; Fonarow GC
Am Heart J; 2008 Oct; 156(4):662-73. PubMed ID: 18926148
[TBL] [Abstract][Full Text] [Related]
30. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
[TBL] [Abstract][Full Text] [Related]
31. Heart failure mortality among older Medicare beneficiaries: association with left ventricular function evaluation and angiotensin-converting enzyme inhibitor use.
Ahmed A; Maisiak R; Allman RM; DeLong JF; Farmer R
South Med J; 2003 Feb; 96(2):124-9. PubMed ID: 12630634
[TBL] [Abstract][Full Text] [Related]
32. Aspirin-angiotensin-converting enzyme inhibitor coadministration and mortality in patients with heart failure: a dose-related adverse effect of aspirin.
Guazzi M; Brambilla R; Reina G; Tumminello G; Guazzi MD
Arch Intern Med; 2003 Jul; 163(13):1574-9. PubMed ID: 12860580
[TBL] [Abstract][Full Text] [Related]
33. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R
J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
[TBL] [Abstract][Full Text] [Related]
34. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes.
Winkelmayer WC; Fischer MA; Schneeweiss S; Wang PS; Levin R; Avorn J
Am J Kidney Dis; 2005 Dec; 46(6):1080-7. PubMed ID: 16310574
[TBL] [Abstract][Full Text] [Related]
35. Can treatment with angiotensin-converting enzyme inhibitors in elderly patients with moderate to severe chronic heart failure be improved by a nurse-monitored structured care program? A randomized controlled trial.
Ekman I; Fagerberg B; Andersson B; Matejka G; Persson B
Heart Lung; 2003; 32(1):3-9. PubMed ID: 12571543
[TBL] [Abstract][Full Text] [Related]
36. Incidence and risk factors of asymptomatic first-dose hypotension with angiotensin-converting enzyme inhibitors in chronic heart failure due to systolic dysfunction.
Thanikachalam S; Manchanda SC
Indian Heart J; 2003; 55(2):167-71. PubMed ID: 12921333
[TBL] [Abstract][Full Text] [Related]
37. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study.
Go AS; Yang J; Ackerson LM; Lepper K; Robbins S; Massie BM; Shlipak MG
Circulation; 2006 Jun; 113(23):2713-23. PubMed ID: 16754803
[TBL] [Abstract][Full Text] [Related]
38. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction.
Ishani A; Weinhandl E; Zhao Z; Gilbertson DT; Collins AJ; Yusuf S; Herzog CA
J Am Coll Cardiol; 2005 Feb; 45(3):391-9. PubMed ID: 15680718
[TBL] [Abstract][Full Text] [Related]
39. Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure.
Zuccalà G; Onder G; Marzetti E; Monaco MR; Cesari M; Cocchi A; Carbonin P; Bernabei R;
Eur Heart J; 2005 Feb; 26(3):226-33. PubMed ID: 15618043
[TBL] [Abstract][Full Text] [Related]
40. Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HF.
Fonarow GC; Abraham WT; Albert NM; Stough WG; Gheorghiade M; Greenberg BH; O'Connor CM; Sun JL; Yancy CW; Young JB;
J Card Fail; 2007 Nov; 13(9):722-31. PubMed ID: 17996820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
